Insulin is, of course, a peptide medicine, while GLP-1-based treatments have established uses in diabetes and obesity. The difficulty lies with the American trade in unapproved ‘wellness peptides’ such as BPC-157, TB-500, KPV, MOTS-c, Semax and epitalon. Unfortunately, Robert F. Kennedy Jr, the US Health Secretary, has placed the authority of the federal government behind the fashion. The HPRA, Medical Council and Pharmaceutical Society should issue joint guidance naming the fashionable compounds and distinguishing them from approved peptide medicines. Good peptide medicines have survived trials and regulatory scrutiny.